Stockscreener 앱 받기
9.74
0.52%
0.05
Oric Pharmaceuticals Inc 주식(ORIC)의 최신 뉴스
Layoff Tracker: Opthea Slashes 80% of Workforce, 50% of Board - BioSpace
Equities Analysts Offer Predictions for ORIC Q3 Earnings - MarketBeat
ORIC Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
ORIC Pharmaceuticals: Strategic Talent and Pipeline Innovation Drive Long-Term Oncology Outperformance - AInvest
ORIC Pharmaceuticals appoints Kevin Brodbeck as chief technical officer By Investing.com - Investing.com Nigeria
Oric Pharmaceuticals appoints Kevin Brodbeck CTO - TipRanks
ORIC Pharmaceuticals appoints Kevin Brodbeck as chief technical officer - Investing.com
ORIC Pharmaceuticals Appoints Kevin Brodbeck, PhD, as Chief Technical Officer to Support Advancement into Late-Stage Clinical Development - Quiver Quantitative
Oric pharmaceuticals taps Kevin Brodbeck as chief technical officer - MarketScreener
ORIC® Pharmaceuticals Expands Leadership Team with the Appointme - GuruFocus
ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer - GlobeNewswire
Former Deciphera Tech Chief Joins ORIC Pharmaceuticals to Lead Phase 3 Development of Two Cancer Drugs - Stock Titan
HC Wainwright & Co. Lowers ORIC Pharmaceuticals' Price Target to $19.00, Maintains "Buy" Rating - AInvest
Volume spikes in ORIC Pharmaceuticals Inc. stock – what they mean2025 Biggest Moves & Verified Entry Point Detection - Newser
Using economic indicators to assess ORIC Pharmaceuticals Inc. potential2025 Volatility Report & Daily Growth Stock Investment Tips - Newser
Oric Pharmaceuticals (NASDAQ:ORIC) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
How to manage a losing position in ORIC Pharmaceuticals Inc.Quarterly Profit Report & Expert Approved Momentum Trade Ideas - Newser
Visualizing ORIC Pharmaceuticals Inc. stock with heatmaps2025 Technical Overview & Daily Stock Trend Watchlist - Newser
Signal strength of ORIC Pharmaceuticals Inc. stock in tech scannersWeekly Trend Summary & Free Technical Confirmation Trade Alerts - Newser
Visual trend scoring systems applied to ORIC Pharmaceuticals Inc.Trade Exit Report & Growth Focused Entry Reports - Newser
Wedbush Predicts Weaker Earnings for Oric Pharmaceuticals - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) Upgraded to Hold at Zacks Research - MarketBeat
Can ORIC Pharmaceuticals Inc. rally from current levels2025 Year in Review & Growth Oriented Trade Recommendations - Newser
What data driven models say about ORIC Pharmaceuticals Inc.’s futureJuly 2025 Catalysts & Consistent Income Trade Recommendations - Newser
Will ORIC Pharmaceuticals Inc. see short term momentumDividend Hike & Safe Capital Growth Tips - Newser
Market reaction to ORIC Pharmaceuticals Inc.’s recent newsWeekly Market Report & Fast Moving Stock Watchlists - Newser
Can volume confirm reversal in ORIC Pharmaceuticals Inc.2025 Sector Review & Risk Adjusted Buy/Sell Alerts - Newser
Oric Pharmaceuticals Faces Potential Setbacks Amid Competitors’ Clinical Trials - MSN
ORIC Pharmaceuticals Inc.’s volatility index tracking explainedWeekly Trade Review & Real-Time Volume Analysis - Newser
Will a bounce in ORIC Pharmaceuticals Inc. offer an exitTrend Reversal & Reliable Entry Point Alerts - Newser
Chart Analysts Warn of Resistance Near ORIC Pharmaceuticals Inc. PriceJuly 2025 Levels & Community Verified Trade Signals - newsyoung.net
JPMorgan Chase & Co. Has Lowered Expectations for Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) Given New $19.00 Price Target at HC Wainwright - MarketBeat
Q3 EPS Estimates for Oric Pharmaceuticals Reduced by Wedbush - Defense World
Will ORIC Pharmaceuticals Inc. continue its uptrend2025 Price Momentum & Community Driven Trade Alerts - Newser
HC Wainwright Lowers Oric Pharmaceuticals (NASDAQ:ORIC) Price Target to $19.00 - Defense World
Oric Pharmaceuticals: Promising Future with Key Trials and Financial Stability Underpinning Buy Rating - TipRanks
Oric Pharmaceuticals' (ORIC) Buy Rating Reiterated at Guggenheim - MarketBeat
XTX Topco Ltd Cuts Stake in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Oric Pharmaceuticals (NASDAQ:ORIC) Given New $17.00 Price Target at JPMorgan Chase & Co. - Defense World
Guggenheim Reaffirms “Buy” Rating for Oric Pharmaceuticals (NASDAQ:ORIC) - Defense World
What makes ORIC Pharmaceuticals Inc. stock price move sharplyEarnings Recap Summary & Fast Entry Momentum Trade Alerts - Newser
A Quick Look at Today's Ratings for Oric Pharmaceuticals(ORIC.US), With a Forecast Between $12 to $23 - 富途牛牛
How to forecast ORIC Pharmaceuticals Inc. trends using time series2025 Trade Ideas & AI Powered Market Entry Strategies - Newser
Jefferies Reiterates Buy Rating on Oric Pharmaceuticals with $23 Price Target. - AInvest
Guggenheim Reaffirms Buy Rating for ORIC Pharmaceuticals with $18 Target Price. - AInvest
Contineum Therapeutics shares fall 1.04% intraday after ORIC Pharmaceuticals reports positive clinical data and financing activity. - AInvest
Moving Average Trends for ORIC Pharmaceuticals Inc. Stock: What They IndicateWeekly Risk Report & Free Risk Controlled Daily Trade Plans - Newser
Guggenheim Reiterates Buy Rating for ORIC Pharmaceuticals | ORIC Stock News - GuruFocus
Guggenheim Keeps Buy Rating, Raises PT for ORIC Pharmaceuticals to $18. - AInvest
ORIC Pharmaceuticals stock price target raised to $23 by Jefferies - Investing.com Canada
Oric Pharmaceuticals Focuses on Lead Clinical Programs - MSN
ORIC Pharmaceuticals Inc. stock momentum explainedEarnings Miss & High Return Trade Opportunity Guides - Newser
Oppenheimer Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛
0.94%
1.72%
자본화:
|
볼륨(24시간):